Merck Serono (Merck KGaA) has signed an exclusive licensing agreement with Affectis Pharmaceuticals of Germany for the development and commercialisation of oral compounds targeting P2X7 receptors. The deal does not include Affectis' lead P2X7 antagonist, AFC-5128, which is in advanced preclinical development, Affectis' CBO Luc St-Onge told Scrip.
Merck Serono (Merck KGaA) has signed an exclusive licensing agreement with Affectis Pharmaceuticals of Germany for the development and commercialisation of oral compounds targeting P2X7 receptors. The deal does not include Affectis' lead P2X7 antagonist, AFC-5128, which is in advanced preclinical development, Affectis' CBO Luc St-Onge told Scrip.
Affectis plans to file an IND early next year for AFC-5128, which is being developed to treat multiple sclerosis and...
Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.
Bimagrumab added to Wegovy increased weight loss and preserved muscle mass, but analysts want to see more safety and efficacy results from a combination with Zepbound.
With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.
Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.
Multi-blockbuster falls short in a giant cell arteritis study.
4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.
The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.
